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Recent cases of infections caused by community-acquired methicillin-resistant Staphylococcus aureus
(MRSA) (CA-MRSA) strains in healthy individuals have raised concerns worldwide. CA-MRSA strains differ
from hospital-acquired MRSAs by virtue of their genomic background and increased virulence in animal
models. Here, we show that in two common CA-MRSA isolates, USA300 and MW2 (USA400), a loss of
penicillin binding protein 4 (PBP4) is sufficient to cause a 16-fold reduction in oxacillin and nafcillin
resistance, thus demonstrating that mecA, encoding PBP2A, is not the sole determinant of methicillin resis-
tance in CA-MRSA. The loss of PBP4 was also found to severely affect the transcription of PBP2 in cells after
challenge with oxacillin, thus leading to a significant decrease in peptidoglycan cross-linking. Autolysis, which
is commonly associated with the killing mechanism of penicillin and -lactams, does not play a role in the
reduced resistance phenotype associated with the loss of PBP4. We also showed that cefoxitin, a semisynthetic
-lactam that binds irreversibly to PBP4, is synergistic with oxacillin in killing CA-MRSA strains, including
clinical CA-MRSA isolates. Thus, PBP4 represents a major target for drug rediscovery against CA-MRSA, and
a combination of cefoxitin and synthetic penicillins may be an effective therapy for CA-MRSA infections.
Methicillin-resistant Staphylococcus aureus (MRSA), the
most common cause of nosocomial infections, was previously
described to be an opportunistic pathogen (1). However, the
incidence of community-acquired MRSA (CA-MRSA) infec-
tions has substantially increased over the last 5 years in healthy
individuals without any known risk factors (4–7, 13, 20, 21, 31,
32, 42, 56). Not only is this medically relevant, but the fact that
methicillin resistance has originated in strains not associated
with nosocomial environments and/or antibiotic exposure is
astonishing and warrants further study. USA300 and MW2
(USA400), representing two distinct clinical isolates, are the
predominant CA-MRSA strains found in the United States (3,
21). Although initially seen in cutaneous infections, USA300
has now become a major cause of sepsis and prosthetic joint
infections, with limited therapeutic options (14, 33, 52, 54).
Although hospital-acquired MRSA (HA-MRSA) and CA-
MRSA strains have similar genomic backgrounds, they do
carry substantial differences, which may explain why commu-
nity-acquired strains are significantly more virulent than their
hospital-acquired counterparts in a mouse model of S. aureus
infection, as they are able to cause a greater level of pathology
in major vital organs, more resistant to killing by human poly-
morphonuclear leukocytes, and capable of causing greater host
cell lysis (57).
Resistance to a greater number of antibiotics has occurred in
S. aureus isolates worldwide. Besides common resistance to
methicillin and -lactams in general, S. aureus has also become
resistant to drugs of last resort such as vancomycin, linezolid,
and daptomycin (14, 25, 27, 49, 51, 54). All S. aureus isolates,
both methicillin-sensitive and -resistant strains, carry three
high-molecular-weight penicillin binding proteins (PBPs),
PBP1, PBP2, and PBP3, to which most -lactam antibiotics
bind. The -lactam antibiotics generally target the transpepti-
dase domain of PBPs, which leads to a reduction in cell wall
cross-linking and, hence, a loss of cell wall integrity (39). PBP4,
the single low-molecular-weight PBP, which has been shown to
have a low affinity for most -lactams, is unique among low-
molecular-weight PBPs in that it possesses transpeptidase and
carboxypeptidase activities (16–18, 34).
Methicillin resistance is achieved by the acquisition of another
high-molecular-weight PBP, namely, PBP2A, encoded by mecA;
this is situated in the chromosome in a genomic island designated
staphylococcal cassette chromosome mec (SCCmec). Unlike in-
nate PBPs, PBP2A has a remarkably low affinity for all -lactams.
Early data have linked PBP4 to low-level methicillin resis-
tance in strains lacking mecA (11, 18, 22, 23). Interestingly, a
loss of PBP4 in MRSA prototypic strain COL had relatively
little effect on -lactam resistance (30). However, the role of
PBP4 in methicillin resistance and -lactam resistance in gen-
eral in CA-MRSA strains has not yet been evaluated.
Here, we showed that a loss of pbp4 in CA-MRSA strains
MW2 and USA300 leads to a dramatic decrease in oxacillin
and nafcillin resistance, while the same deletion does not con-
fer a similar phenotype in the HA-MRSA strains COL and
N315 and vancomycin-intermediate S. aureus (VISA) strain
Mu50. We also discovered that a loss of PBP4 has a dramatic
impact on PBP2 transcription in cells challenged with oxacillin
in CA-MRSA strain MW2 but not in HA-MRSA strain COL.
The defect in PBP2 expression may partially contribute to the
lower MIC; however, it was not the only factor contributing to
the resistance mechanism, since the complementation of pbp2
in trans did not significantly alter -lactam resistance in pbp4
mutants. The decrease in PBP2 combined with a loss in PBP4
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might, however, explain the more significant loss in peptidogly-
can cross-linking in CA-MRSA than in HA-MRSA. We fur-
ther demonstrate that cefoxitin, a -lactam that binds PBP4
irreversibly, renders CA-MRSA strains such as MW2 and
USA300 as well as clinical isolates from skin and soft tissue
infections sensitive again to oxacillin (MIC  1 g/ml). These
findings have heightened the role of PBP4 in conferring
methicillin resistance in CA-MRSA isolates. The combination
of cefoxitin and oxacillin might constitute a valid therapeutic
approach for treating CA-MRSA infections.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Escherichia coli strain XL-1 Blue was
used in molecular cloning experiments. The wild-type and mutant S. aureus
strains used in this study are listed in Table 1. Luria-Bertani medium (Becton
Dickinson) was used for the culture of E. coli, while S. aureus was cultured in
Mueller-Hinton broth (Becton Dickinson) supplemented with 25 g/ml Ca2,
12.5 g/ml Mg2, and 2% NaCl (cation-supplemented Mueller-Hinton broth
[CSMHB]). When appropriate, antibiotics were added to the media at the
following concentrations: ampicillin at 100 g/ml for E. coli and chloramphenicol
at 10 g/ml and erythromycin at 2.5 g/ml for S. aureus. Chloramphenicol was
routinely used to maintain selection for pEPSA5- and pSK236-based plasmids
(12). All antibiotics were obtained from Sigma.
Collection of clinical isolates and fast screening of CA-MRSA versus HA-
MRSA strains. Two independent batches of clinical isolates were obtained from
the Dartmouth Hitchcock Medical Center, Lebanon, NH. The first group in-
cluded 200 blood MRSA isolates subcultured on 5% Columbia sheep blood agar
(Remel), while the second group involved 30 MRSA isolates from complicated
skin and soft tissue infections (CSSTI). All strains were grown overnight in
CSMHB broth and streaked onto selective mannitol salt agar plates for confir-
mation. DNA extraction was performed on 500 l of cultures. PCR was per-
TABLE 1. Strains and plasmids
Strain or plasmid Description Reference or source
Strains
S. aureus
RN4220 MSSA derivative of 8325-4, acceptor of foreign DNA 35
MW2 (USA400) CA-MRSA, wild-type strain 3
MW2 pbp3 pbp3 in-frame deletion mutant of parental strain MW2 This study
MW2 pbp4 pbp4 in-frame deletion mutant of parental strain MW2 This study
MW2 pbp3/4 pbp3 pbp44 in-frame double deletion mutant of parental strain MW2 This study
MW2 pbp4::pbp4 pbp4 complemented with pbp4 with pMAD cycling This study
MW2 pbp4 Wild-type complemented with pMAD cycling This study
MW2 ex CA-MRSA; wild-type strain cured of plasmid pMW2 This study
MW2-ex::pMW2 CA-MRSA; wild type cured of plasmid and complemented with pMW2 This study
MW2-ex pbp3 pbp3 in-frame deletion mutant of parental strain MW2 ex This study
MW2-ex pbp4 pbp4 in-frame deletion mutant of parental strain MW2 ex This study
MW2-ex pbp3/4 pbp3 pbp4 in-frame double deletion mutant of parental strain MW2 ex This study
COL HA-MRSA; wild-type strain 19
COL pbp3 pbp3 in-frame deletion mutant of parental strain COL This study
COL pbp4 pbp4 in-frame deletion mutant of parental strain COL This study
COL pbp3/4 pbp3 pbp4 in-frame double deletion mutant of parental strain COL This study
USA300 CA-MRSA; wild-type strain 9
USA300 pbp4 pbp4 in-frame deletion mutant of parental strain USA300 This study
USA300 pbp4 Wild type complemented with pMAD cycling This study
N315 HA-MRSA; wild-type strain 36
N315 pbp4 pbp4 in-frame deletion mutant of parental strain N315 This study
Mu50 HA-MRSA/VISA; wild-type strain 36
Mu50 pbp4 pbp4 in-frame deletion mutant of parental strain Mu50 This study
Newman arlRS arlRS in-frame deletion of methicillin-sensitive strain Newman This study
E. coli strain XL-1 blue General laboratory cloning strain 50
Plasmids
pMAD Allelic replacement vector to generate S. aureus mutant strains 2
pMAD-CM pMAD containing the cat gene from pSK236 using NaeI This study
pEPSA5 Ectopic expression vector (pEPSA5) for genes in S. aureus 12
pALC1484 Derivative of pSK236 containing recombinant gfpuvr gene 29
pMAD MW2 pbp3 pMAD containing 0.8-kb up- and downstream MW2 fragments of pbp3 This study
pMAD MW2 pbp4 pMAD containing 0.8-kb up- and downstream MW2 fragments of pbp4 This study
pMAD MW2 pbp4 pMAD containing the pbp4 gene and 0.8-kb up- and downstream from MW2 This study
pMAD COL pbp3 pMAD containing 0.8-kb up- and downstream COL fragments of pbp3 This study
pMAD COL pbp4 pMAD containing 0.8-kb up- and downstream COL fragments of pbp4 This study
pEPSA5::pbp4 pEPSA5 containing a 1.38-kb DNA fragment containing the pbp4 coding region
including its own ribosome binding site from MW2 at BamHI/XbaI
This study
pEPSA5::pbp2 pEPSA5 containing a 2.18-kb DNA fragment containing the pbp2 coding region
including its own ribosome binding site from MW2 at XmaI/BamHI
This study
pEPSA5::mecA pEPSA5 containing a 2-kb DNA fragment containing the mecA coding region
including its own ribosome binding site from MW2 at BamHI/XbaI
This study
pALC3711 pALC1484 with a 970-bp promoter fragment of pbp2 (P1) fused with the gfpuvr
reporter gene at the EcoRI/XbaI sites
This study
pALC4677 pALC1484 with a 180-bp promoter fragment of pbp2 (P2) fused with the gfpuvr
reporter gene at the EcoRI/XbaI sites
This study
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formed on extracted DNAs with custom oligonucleotides (Integrated DNA
Technology) specific for mecA (this study), pvl (38), and the three genes that we
found to be specific for SCCmec type IV in CA-MRSA, MW0042, MW0043, and
MW0047 (this study), without assigned functions. DNA amplification of mecA
was used as a control to confirm that all strains were MRSA. DNAs from S.
epidermidis, E. coli, and Streptococcus pneumoniae were used as negative controls
to confirm the specificity of the oligonucleotides. After amplification for 30 cycles
(5 min of denaturation at 95°C, 30 s of annealing at 54°C, and 1 min of extension
at 72°C), PCR products were resolved by electrophoresis through 1.5% agarose
gels stained with ethidium bromide. Given the number of clinical isolates tested,
only a small random group of PCR products were subjected to DNA sequencing
to confirm specificity. S. aureus strains COL, Mu50, N315, and MRSA252 all
tested negative for MW0042, MW0043, and MW0047 and pvl, while USA300 and
MW2 were positive controls for this PCR. The primer sequences for mecA,
MW0042, MW0043, and MW0047 were as follows: mecA-UP (5-GGTACTGC
TATCCACCCTCAAA-3), mecA-LOW (5-TTACGACTTGTTGCATACCAT
CA-3), MW0042-UP (5-ATTGGCAGAAATAAACAAAACG-3), MW0042-
LOW (5-TCGTTTAATTTTTTCCCAAACTC-3), MW0043-UP (5-GTTTCA
GTTGGTGTTGAAGATCC-3), MW0043-LOW (5-CCTATAATTTTCGAT
AGATTCGTG-3), MW0047-UP (5-AGGCATATAAAGAAGCAGGAAAG-
3), and MW0047-LOW (5-CACACTGTTTTCCTACGATATTTG-3).
Susceptibility testing and synergy assay. MICs and minimum bactericidal
concentrations (MBCs) were determined for each isolate and mutant in triplicate
by microdilution techniques using an inoculum of 5 	 105 CFU/ml according to
Clinical and Laboratory Standards Institute guidelines (6). For each mutant,
three independent clones were tested. For MBC determinations, aliquots (5 l)
from clear wells were plated onto tryptic soy agar drug-free plates followed by
incubation at 37°C for 24 and 48 h. MIC data were reported as median values
from at least three independent experiments for each antibiotic. Strains contain-
ing pEPSA5-based plasmids were tested with and without xylose induction, but
chloramphenicol was not added to avoid interference with -lactam resistance
evaluation. To assess the synergistic effect of cefoxitin plus oxacillin, we first
determined the MIC of cefoxitin for both CA-RMSA and HA-MRSA strains;
0.25	 MIC of cefoxitin was then used in combination with a twofold dilution of
oxacillin to ascertain their synergistic effect. The correct inocula were confirmed
by plating serial dilutions onto agar. The synergistic inhibitory activity of cefoxitin
with oxacillin was scored at 24 and 48 h. Cefuroxime, a -lactam with a very low
affinity for PBP4, was also tested as a negative control in combination with
twofold dilutions of oxacillin and was found to have no effect whatsoever on
oxacillin MICs.
Population analysis. Antibiotic susceptibilities for MW2 were also determined
by population analysis, as described previously (55). Briefly, the cells were grown
overnight in CSMHB at 37°C, and four different dilutions of the bacterial culture
(100, 102, 104, and 106) were then plated onto control plates without anti-
biotic and onto plates containing a series of twofold dilutions of cefoxitin,
oxacillin, or oxacillin combined to one-fourth the MIC of cefoxitin. The plates
were incubated at 37°C for 48 h, and colonies were counted.
DNA and computational techniques. Plasmid DNA was isolated by standard
techniques (Qiagen) from E. coli and from lysostaphin digestion of S. aureus.
Chemically competent E. coli or electrocompetent S. aureus cells were used for
transformation. New England Biolabs restriction endonucleases and ligases were
used according to the manufacturer’s recommendations. Iproof DNA polymer-
ase from Bio-Rad Laboratories was used to generate all DNA fragments for
deletions, promoter fusions, and ectopic expressions in pEPSA5. The fidelity of
all DNA sequences generated by PCR was verified by fluorescently labeled
dideoxynucleotide sequencing (Big Dye terminators; PE Applied Biosystems).
Construction of S. aureus mutants. All mutants were generated with an in-
frame deletion of target genes by allelic replacement using the temperature-
sensitive plasmid pMAD. Briefly, 0.8-kb PCR products upstream and down-
stream of targeted sequences were generated and ligated by gene SOEing (26).
The resulting 1.6-kb product was digested, gel purified, cloned into pMAD
using the same restrictions sites, and transformed into E. coli. Colony PCR was
performed on E. coli transformants. Plasmids from positive clones were verified
by digestion analysis and then used to transform S. aureus RN4220, selecting for
erythromycin- or chloramphenicol-resistant and blue colonies at 30°C. Plasmid
from RN4220 was sequenced and used to transform S. aureus strains MW2,
COL, USA300, N315, and Mu50, for which the gene was to be deleted. The
process of allelic replacement was described previously (2). For Mu50, N315, and
USA300, which are erythromycin resistant, a modified pMAD vector was con-
structed (pMAD-CM) by cloning the chloramphenicol acetyltransferase (cat194)
gene from pSK236 into the NaeI site of pMAD. All chromosomal deletions were
verified by PCR and DNA sequencing. A minimum of three independent clones
for each mutant were generated in every genomic background analyzed and
studied further. The resulting deletion strains were devoid of the entire open
reading frame (ORF) for both pbp3 and pbp4. The same pMAD system was also
utilized to reinsert the pbp4 ORF into the MW2 pbp4 and pbp3 pbp34
mutants and the USA300 pbp4 mutants for complementation. The sequences of
DNA primers used in this study are available from the authors upon request.
Curing of plasmid, loss of cadmium resistance, -lactamase production, and
mecA repression. The loss of plasmid pMW2 in strain MW2 and, therefore, the
loss of resistance to cadmium and -lactamase production were investigated by
passaging MW2 at 44°C and screening single colonies by a replica plate method.
Colonies that were sensitive to cadmium and tested positive for the loss of
-lactamase production as determined by nitrocefin assay were tested for plas-
mid loss by agarose gel electrophoresis and PCR with oligonucleotides specific
for blaIRZ. The expression of mecA in the strain cured of the plasmid (MW2 ex)
was evaluated by Northern blot analysis.
Isolation of RNA and Northern blot hybridization. Cultures of S. aureus grown
overnight were diluted 1:100 in 40 ml of CSMHB broth and grown with shaking
to exponential phase (A650 of 0.7) in 200-ml flasks. At an optical density (OD) of
0.7 (Spectronic 20 using 18-mm borosilicate glass tubes), total RNA was ex-
tracted from 10 ml of culture, while the remaining 30 ml was divided evenly into
three glass tubes, one with no antibiotic, the second with 10	 MIC of oxacillin,
and the third with 10	 MIC of vancomycin. After growing for an additional 60
min, RNAs from all samples were extracted by using a Trizol-glass bead method
as described previously (40). The concentration of total RNA was determined by
measuring the absorbance at 260 nm. Ten micrograms each of total RNA was
analyzed by Northern blotting as described previously (6). Each DNA probe (350
bp) was generated by PCR from chromosomal templates. For the detection of
specific transcripts, gel-purified DNA probes were radiolabeled with
[
-32P]dCTP by using the random-primed DNA labeling kit (Roche Diagnostics
GmbH) and hybridized under aqueous-phase conditions at 65°C. The blots were
subsequently washed, and bands were visualized by autoradiography.
Transcriptional fusion studies of PBP2 promoters linked to the GFPuvr re-
porter gene. To confirm the effect of the pbp4 deletion on pbp2, we cloned both
pbp2 promoters in pALC1484, a derivative of pSK236 containing the promoter-
less gfpuvr to generate transcriptional fusions. Clustal W analysis revealed that the
promoter sequences from HA-MRSA strain COL and CA-MRSA strain MW2
are 100% identical. Restriction analysis and DNA sequencing confirmed the
orientation and authenticity of the promoter fragments upstream of the reporter
gene. Recombinant plasmids were introduced into S. aureus RN4220, purified,
and electroporated into wild-type MW2, COL, and their isogenic pbp mutants.
Cultures grown overnight were diluted 1:100 in CSMHB with chloramphenicol
and grown to an OD at 650 nm (OD650) of 0.7; bacterial cultures were then
exposed to no antibiotic, oxacillin, or vancomycin at 10	 MIC for 60 min.
Aliquots of 200 l were transferred before antibiotic challenge and every hour
thereafter into microtiter wells to assay for cell density (OD650) and fluorescence
in an FL600 fluorescence reader (BioTek Instruments). Promoter activation was
plotted as the mean fluorescence/OD650 ratio, using the average values from
triplicate readings from three clones per strain.
Ectopic expression of genes in S. aureus. To complement the mutant strains,
we also utilized expression plasmid pEPSA5, which can be induced for expres-
sion with xylose (1%) or repressed by glucose (1%) (11). For pEPSA5-mediated
expression, genes were amplified by PCR, and products were digested, gel pu-
rified, ligated into pEPSA5, and transformed into E. coli XL-1 Blue. Plasmids
from positive clones in E. coli were verified by digestion analysis and then used
to transform S. aureus RN4220. The plasmids were then introduced into MW2,
USA300, and their isogenic pbp4 mutants as described above. To confirm the
correct induction with 1% xylose with recombinant pEPSA5, reverse transcrip-
tion-PCR of the specific transcript was performed on RNAs before and after
xylose induction. Briefly, total RNA was extracted, resuspended in diethyl pyro-
carbonate water, and treated with Turbo DNase (Ambion). cDNA was generated
from 1 g of cellular RNA using the Transcriptor first-strand cDNA synthesis kit
(Roche). Regular PCR was then performed on cDNAs using oligonucleotides
specific for each gene. Nonetheless, the basal level of expression was always
observed without adding exogenous xylose to culture media.
Triton X-100-induced autolysis assays in static cultures. The autolysis assay
was performed as described previously (28). Briefly, strains grown overnight in
tryptic soy broth were diluted and grown to mid-logarithmic phase (A650 of 0.7).
Cells were washed twice in cold sterile distilled water and resuspended in 10 ml
of 0.05 M Tris-HCl (pH 7.2) containing 0.05% Triton X-100 at 30°C, and the A600
was measured every 30 min. Data are expressed as the percent loss of A600 at the
indicated times compared to the zero time point. Each data point represents the
mean and standard deviation from three independent experiments.
Effect of Triton X-100 on growing cells. The effect of Triton X-100 was assayed
on actively dividing cells as described previously (28). Briefly, cultures grown
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overnight were diluted to an OD650 of 0.1 in CSMHB with different concentra-
tions of Triton X-100. Cells were incubated at 37°C with shaking, and ODs were
recorded hourly for 7 to 8 h. Each data point represents the mean and standard
deviation from three independent experiments.
Zymogram analysis. Zymogram analysis was conducted to detect alterations in
autolysin activity as previously described, with minor alterations (28). Heat-killed
RN4220 cells were incorporated into an 8% sodium dodecyl sulfate (SDS)-
polyacrylamide gel at 10 mg/ml wet weight. Autolytic enzymes were extracted
from 10 ml of culture grown to an A650 of 0.7 using 100 l of 4% SDS. Equivalent
amounts of proteins were separated on an SDS-polyacrylamide gel. Resolved
proteins were allowed to renature overnight in water and incubated with 0.1%
methylene blue to visualize clear bands, representing an area of RN4220 cell
lysis. The assay was repeated three times, with a representative experiment
shown.
Electron microscopy. Cultures grown overnight were reinoculated in fresh
CSMHB and grown to an OD650 of 0.7. One 1-ml aliquot was harvested by
low-speed centrifugation. Oxacillin was then added to the other two specimens to
achieve a final concentration of 1	 MIC and 10	 MIC, with cells growing at
37°C for an additional 60 min, and then harvested. All specimens described
above were then fixed with 2% glutaraldehyde–1% paraformaldehyde and post-
fixed with OsO4. Ultrathin sections were stained with 2% methanolic uranyl
acetate and lead citrate and examined with a Jeol JEM 1010 electron microscope.
Analysis of peptidoglycan. Peptidoglycan and muropeptide preparation and
consequent high-performance liquid chromatography (HPLC) separation were
performed as described previously (8). Briefly, cell wall extracts were purified by
shaking bacteria with glass beads, followed by enzymatic digestion of DNA,
RNA, and proteins. Peptidoglycan was then obtained by treating cell wall ex-
tracts with hydrofluoric acid. Muropeptides obtained by digesting peptidoglycan
with mutanolysin (Sigma) were separated by HPLC and detected by measuring
the absorption at 206 nm. Quantification was made by measuring the area of
each individual peak and expressing it as a percentage of the total area of all
peaks. Peaks of interest were desalted and analyzed by matrix-assisted laser
desorption ionization mass spectrometry using yano-4-hydroxycinnamic acid as
the matrix-assisted laser desorption ionization matrix at the Mass Spectrometry
Service at the ITQB, Lisbon, Portugal.
RESULTS
Construction and characterization of PBP4 mutants. The
role of PBPs and their contribution to -lactam resistance in
CA-MRSA have never been investigated. For this purpose, we
deleted the ORFs encoding PBP3 (MW1504) and PBP4
(MW0604), both of which are transcribed monocistronically
and reside at different parts of the chromosome in HA-MRSA
strain COL and CA-MRSA strain MW2 (USA400). The PBP4
gene was also deleted in the hospital-acquired strains Mu50
and N315 and community-acquired strain USA300. We also
tried but failed to obtain viable clones for PBP1 and PBP2.
The PBP4 gene shares a 400-nucleotide intercistronic region
with the divergently transcribed abcA (MW0605), encoding an
ATP binding cassette transporter that has been shown to be
involved in cell wall metabolism and division (10). Accordingly,
we assessed and confirmed that our pbp4 deletion did not lead
to a polar effect on both the upstream (MW0603 [teichoic acid
biosynthesis protein D {tagD}]) and the downstream (abcA)
genes by Northern blot analysis. A minimum of three indepen-
dent clones were analyzed for each mutant. Hypersensitivity to
oxacillin and nafcillin was first determined by assessing the
MICs for parents and isogenic pbp mutants (Table 2). Oxacillin
and nafcillin resistances were not altered in pbp3, pbp4, or
double mutants of COL, in concordance with previously re-
ported results (30, 48). Similarly, the loss of PBP4 in HA-
MRSA strains N315 and Mu50 resulted in a minimal or no
decrease in MICs of both oxacillin and nafcillin. Remarkably,
a loss of pbp4 in MW2 and USA300 resulted in a 16-fold
reduction in oxacillin and nafcillin MICs (from 64 to 4 g/ml
and from 16 to 1 g/ml, respectively), while a deletion in pbp3
had no effect.
Effect of pbp4 deletion on pbp2 and pbp2A expression. The
ability of S. aureus to survive in the presence of -lactams relies
upon its ability to express PBP2A, the alternative PBP encoded
by mecA. The transglycosylase domain of PBP2 is a second
crucial determinant for -lactam resistance in MRSA strains
(47). Recent data have shown that PBP2 affects the expression
of mecA and also functions cooperatively with the transpepti-
dase activity of PBP4 (15, 37). To assess whether the loss of
resistance in the pbp4 mutants of CA-MRSA was due to de-
fective pbp2 or mecA expression, we performed Northern blots
and showed that a loss of pbp4 diminished the induced expres-
sion of pbp2 upon exposure to both cell wall-active antibiotics
oxacillin and vancomycin in CA-MRSA MW2 (Fig. 1A) but
not in HA-MRSA COL (Fig. 1C). In contrast, the transcript
level of mecA was not altered in the pbp4 mutants of both
MW2 and COL (Fig. 1B to D). The defect in the induction of
pbp2 expression with oxacillin in the pbp4 mutant of MW2 was
restored to wild-type levels upon complementation (Fig. 1E),
while the empty vector had no effect. To confirm the effect of
the pbp4 deletion on pbp2 expression, the P1 (2.9-kb tran-
script) and P2 (2.2-kb transcript) promoters of pbp2 were fused
to a promoterless gfpuvr reporter gene in shuttle plasmid
pALC1484. Both P1 and P2 promoters were induced by ox-
acillin at 10	 MIC in MW2 but not in the pbp4 or pbp4 pbp3
mutant, confirming the Northern blot data (Fig. 2A to D). The
differences in green fluorescent protein (GFP) values were not
due simply to a difference in growth between the wild-type and
the mutant strains because the ODs after 4 h of oxacillin
TABLE 2. Oxacillin, nafcillin, and cefoxitin MICs for wild-type and
mutant strainsa
Strain PFGE serotype
MIC (g/ml)
OXA NAF FOX
MW2 (USA400) (wild type) USA400 64 16 64
MW2 pbp3 USA400 64 16 64
MW2 pbp4c USA400 4 1 64
MW2 pbp3/4c USA400 4 1 64
MW2 pbp4::pbp4 USA400 64 16 64
MW2 exb USA400 128 16 16
MW2 ex pbp3 USA400 128 16 32
MW2 ex pbp4c USA400 2 1 16
MW2 ex pbp3/4c USA400 1 1 32
USA300 (wild type) USA300 64 16 64
USA300 pbp4 USA300 4 1 64
USA300 pbp4::pbp4c USA300 64 16 64
COL wild-type USA500 256 64 128
COL pbp3 USA500 256 64 128
COL pbp4 USA500 256 64 128
COL pbp3/4 USA500 256 64 128
N315 (wild type) USA100 256 64 64
N315 pbp4 USA100 128 64 64
Mu50 (wild type) USA100 256 256 256
Mu50pbp4 USA100 256 256 256
a Determinations of MICs of oxacillin, nafcillin, and cefoxitin for parental and
isogenic pbp mutants were performed according to CLSI (formerly NCCLS)
protocols. Bacteria, grown to an OD650 of 1, were added to CSMHB to a final
concentration of 5 	 105 CFU/ml.
b MW2 ex, MW2 cured of plasmid pMW2.
c pbp4 is essential for -lactam resistance in CA-MRSA strains MW2 and
USA300 but not in HA-MRSA COL, N315, and Mu50 (MRSA/VISA) (as shown
bolded and highlighted).
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induction were virtually identical among all strains. Addition-
ally, differences in GFP values were still apparent even after
overnight growth, thus confirming that the disparity was due to
a transcriptional defect instead of a growth defect. In contrast,
differences in the induction of pbp2 after antibiotic challenge
were still apparent in pbp4 and pb4 pbp3 mutants of strain COL
(Fig. 2E to H), wherein both P1 and P2 promoters were equally
upregulated in the presence of oxacillin and vancomycin in
both wild-type and mutant strains.
Complementation studies. To exclude chromosomal rear-
rangement or an ectopic point mutation as the cause for the
loss of resistance, plasmid pMAD was used to reintroduce
pbp4 into the chromosome of pbp4 and pbp3 pbp4 mutants
of MW2. Both chromosomally complemented strains MW2
pbp4::pbp4 and USA300 pbp4::pbp4 regained wild-type lev-
els of oxacillin resistance (Table 2). Similar results were ob-
tained when the ORF encoding PBP4 was cloned in the xylose-
inducible system pEPSA5, while the empty vector had no effect
(data not shown). However, the expression of PBP2 or PBP2A
in pEPSA5 did not alter the MIC in both pbp4 and pbp3 pbp4
mutants (data not shown). Notably, the reduction in oxacillin
resistance in the pbp4 mutants of MW2 and USA300 was not
fully attributable to pbp2 because the expression of pbp2 from
the inducible plasmid pEPSA5 did not restore oxacillin resis-
tance in the pbp4 mutant, with the MIC still at 4 g/ml. To
further exclude possible polar effects due to genetic manipu-
lation of the ORFs encoding PBP3 and PBP4, transcription
profiles of genes upstream and downstream of both ORFs
were examined in MW2, revealing no significant alterations
between the wild type and the mutants (data not shown).
MecA regulation-expression and -lactam resistance. The
hospital-acquired strain COL and the community-acquired
strain MW2 have substantially different regulations of mecA.
Both strains lack the gene encoding mecI, a repressor of mecA
expression. However MW2 carries the blaIRZ operon on plas-
mid pMW2, which codes for the penicillinase-regulatory gene
blaI, the membrane sensor blaR, and the penicillinase gene
blaZ; blaI was previously found to regulate the expression of
mecA in trans (41). To ascertain the role of plasmid pMW2 in
the regulation of mecA in MW2, we cured the plasmid to
generate the derivative strain MW2 ex. This strain resulted in
the constitutive expression of mecA, similar to what has been
found with COL (Fig. 3). In the complemented strain obtained
by reintroducing plasmid pMW2 into MW2 ex, the expression
of mecA was again repressed unless oxacillin was added to
induce expression. The loss of pbp4 in MW2 ex, with or without
a concomitant loss of pbp3, led to a more substantial decrease
in oxacillin resistance than in MW2, with a 64-fold reduction in
the oxacillin MIC for the pbp4 mutant (from 128 to 2 g/ml in
MW2 ex versus 64 to 4 g/ml in MW2) and a 128-fold reduc-
tion for the pbp3 pbp4 double mutants (from 128 to 1 g/ml in
MW2 ex versus 64 to 4 g/ml in MW2), respectively (Table 2).
Effect of pbp4 deletion on genes that regulates autolysis and
murein hydrolase activity. To assess whether hypersensitivity
to -lactams in pbp4 mutants of MW2 was due to an effect on
regulatory autolytic genes and/or increased murein hydrolase
activity, Northern blots were conducted with DNA probes spe-
cific for the following genes: sarA, sarR, sarT, sarS, mgrA, atl,
lytM, lytN, lysR, lytSR, cidABC, and lrgAB. Besides a minor
difference in sarA transcription in all pbp mutants, all other
FIG. 1. Loss of pbp4 affects the expression of pbp2 in cells chal-
lenged with oxacillin in CA-MRSA strain MW2 but not in HA-MRSA
strain COL. Shown is Northern blot analysis of pbp2 and mecA expres-
sion (A and B, MW2; C and D, COL) in cultures with no antibiotic,
oxacillin, or vancomycin at 10	 MIC for 1 h. Blots were hybridized
with a DNA probe specific for pbp2 (A and C) or mecA (B and D)
radiolabeled with [
-32P]dCTP. (Bottom) Ethidium bromide-stained
rRNAs indicating equivalent amounts of RNA in each sample. Lane 1,
RNA from cells at an OD650 of 0.7 before antibiotic induction; lanes 2
to 4, RNA from cells at 1 h with no antibiotic, oxacillin, and vanco-
mycin at 10	 MIC, respectively. (E) Northern blot analysis of pbp2
expression in MW2 and its isogenic mutants carrying pPEPSA5::pbp4.
Complementation of PBP4 in trans restored pbp2 transcripts to wild-
type levels, while the empty vector had no effect (data not shown).
Lane 1, RNA from cells at 0.7 OD units before antibiotic induction;
lanes 2 to 4, RNA from cells at 1 h with no antibiotic, oxacillin, and
vancomycin at 10	 MIC, respectively.
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transcript levels tested were similar between wild types and
their isogenic mutant strains (data not shown). Zymogram
analysis also did not reveal enhanced autolysis, with similar
murein hydrolase activities between MW2 and all pbp mutants
(Fig. 4A and B). We also checked the effect of the nonionic
detergent Triton X-100 on static and actively growing cells.
However, no differences in ODs were observed between the
wild type and the mutants in static cultures exposed to 0.05%
FIG. 2. Expression of GFPuvr driven by pbp2-P1 (A and B, MW2; E and F, COL) and pbp2-P2 (C and D, MW2; G and H, COL) promoters
in uninduced (A, C, E, and G) and induced (B, D, F, H) cultures with 10	 MIC of oxacillin. Cultures grown overnight were reinoculated in
CSMHB and grown to mid-log phase followed by the addition of no antibiotic or 10	 MIC of oxacillin. Promoter activity was plotted as the mean
fluorescence/OD650 from three clones in triplicates. The experiments were repeated three times, with one set shown. The “*” indicates statistical
significance of the indicated strain to MW2 at 3 to 6 h after antibiotic challenge by the paired Student’s t test (P  0.001).
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Triton X-100 at 30°C (Fig. 4C), thus suggesting that the
amounts of autolysins in the mutated strain are equal to those
associated with the wild type, while the two-component system
arlRS mutant in the Newman background, used as a positive
control, did reveal increased autolysis. In growing cultures at
37°C with Triton X-100, both pbp4 and pbp4 pbp3 mutants
showed a reduced rate of the rise in the OD compared with
that of the wild type or complemented pbp4 mutant. This
discrepancy in the rise of OD between static and actively grow-
ing cultures is more consistent with a defect in cell wall bio-
synthesis than with augmented autolytic activity (Fig. 4D).
pbp4 deletion affects the level of peptidoglycan cross-linking.
Previous studies linked the loss of PBP4 to a reduction in
peptidoglycan cross-linking in methicillin-sensitive S. aureus,
MRSA COL, and glycopeptide-resistant S. aureus strains (53).
HPLC elution profiles of muropeptide species released by mu-
ramidase digestion of peptidoglycan from MW2 and its pbp
mutants (Fig. 5) divulged an increase in monomers, dimers,
trimers, and tetramers and a concomitant reduction in the
proportion of highly cross-linked muropeptides (tetramer) in
pbp4 mutants but not in pbp3 mutants.
Effect of loss of pbp4 on cell morphology and septum for-
mation. Electron microscopy revealed no major differences
between MW2 and pbp4 mutants without -lactam challenge,
while the exposure of cells to oxacillin led to incomplete sep-
tum formation, irregularly placed septa, and rough cell wall
surfaces in parents and mutant strains alike (data not shown).
Synergistic effect of cefoxitin and oxacillin in CA-MRSA
strains. Although PBP4 binds poorly to many -lactams, it
FIG. 3. Northern blot analysis of mecA expression in CA-MRSA
strain MW2 (USA400) and its isogenic strain MW2 ex, cured of plas-
mid pMW2. The expression of mecA was assessed in cultures with no
antibiotic, oxacillin, or vancomycin at 10	 MIC for 1 h. Blots were
hybridized with a DNA probe specific for mecA radiolabeled with
[
-32P]dCTP. (Bottom) Ethidium bromide-stained rRNAs indicating
equivalent loading of RNA in each sample. Lane 1 corresponds to
RNA from cells at 0.7 OD units before induction with oxacillin; lanes
2 to 4 correspond to RNA from cells at 1 h with no antibiotic induction,
oxacillin at 10	 MIC, and vancomycin at 10	 MIC, respectively.
FIG. 4. Zymogram analysis and autolysis assays of pbp4 mutants with 1% Triton X-100. (A) Zymogram analysis of cell extracts from S. aureus
MW2 and its isogenic pbp mutants. Lanes: 1, molecular size markers; 2, MW2; 3, pbp3; 4, pbp4; 5, pbp3 pbp4. Equivalent amounts of cell
extracts were separated on a 12% SDS-polyacrylamide gel containing heat-killed S. aureus RN4220 cells, treated with 1% Triton X-100, and stained
with 1% methylene blue. Areas of murein hydrolase activity are indicated by clear zones. (B) Coomassie-stained gel of A. (C) Triton X-100-induced
autolysis assay under static conditions. After adding Triton X-100 (0.05%), the autolysis of mid-exponential-phase cultures was determined at 30°C
without shaking by serial OD measurements. The arlRS mutant of strain Newman was used as a positive control. (D) Effect of Triton X-100 on
growing cells of MW2 and its isogenic mutants. Cultures grown overnight, diluted to an OD650 of 0.1 in CSMHB with 0.05% Triton X-100, were
grown at 37°C with shaking. The “*” indicates statistical significance of pbp3 and pbp3 pbp4 mutants to MW2 at 4- to 9-h time points by the paired
Student’s t test (P  0.001).
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does bind cefoxitin with high affinity (46). We thus tested the
synergistic effect of cefoxitin (0.25	 MIC) in combination with
oxacillin by determining the MIC of oxacillin with CA-MRSA
and HA-MRSA strains (Table 3). Oxacillin resistance was min-
imally altered by the presence of cefoxitin in HA-MRSAs and
VISA strain Mu50. Remarkably, a synergistic inhibitory effect
of cefoxitin with oxacillin was found with MW2 and USA300,
with both strains being unable to grow at 1 g/ml of oxacillin
at both the 24- and 48-h time points. We also tested the MBC
of oxacillin, cefoxitin, and oxacillin combined to one-fourth the
MIC of cefoxitin in both CA-MRSA and HA-MRSA strains
(Table 4). The MBC of oxacillin for both MW2 and USA300
was 256 g/ml, while that of cefoxitin was 256 g/ml. How-
ever, the MBC of oxacillin with one-fourth the MIC of cefox-
itin was 1 g/ml for both MW2 and USA300 (Table 4).
Population analysis of susceptibility to oxacillin, cefoxitin, and
oxacillin combined to one-fourth the MIC of cefoxitin to detect
trends and the potential for developing resistance was also
evaluated (Fig. 6). Our population analysis continued to dem-
onstrate the synergistic inhibitory effect of cefoxitin and oxacil-
lin on CA-MRSA strain MW2, with the MIC of oxacillin drop-
ping to a level that is still clinically achievable, from 128 to 0.5
g/ml.
Synergistic effect of cefoxitin and oxacillin in clinical iso-
lates and CA-MRSA strains. To assess the efficacy of the
synergistic combination of cefoxitin and oxacillin on other CA-
MRSA strains, we screened 200 MRSA isolates, blinded with
respect to origin, from Dartmouth-Hitchcock Medical Center,
Lebanon, NH. Analysis of the type IV SCCmec element, vir-
tually identical between MW2 and USA300, allowed us to
identify three genes conserved in the CA-MRSA background
but not in other known MRSA genomes. PCR of chromosomal
DNAs with oligonucleotides specific for mecA, pvl (38), and
the three specific genes for CA-MRSAs (MW0042, MW0043,
FIG. 5. Effect of deleting pbp3 and pbp4 on MW2 peptidoglycan composition. Peptidoglycan was prepared from exponentially grown bacteria
in tryptic soy broth medium, as described previously (15). The muropeptide composition of peptidoglycan was analyzed by HPLC. The identity of
each peak was assigned based on the specific retention time in comparison to previously identified peaks of strain COL, with arrows pointing to
highly cross-linked muropeptides present in MW2 and its isogenic pbp3 mutant but reduced in pbp4 and pbp3 pbp4 mutants. Quantification of the
area of eluted peaks was carried out using Shimadzu LC solution software, with the data presented as a percentage of the total identified peaks.
TABLE 3. Oxacillin and cefoxitin MICs for wild-type CA-MRSA and HA-MRSA isolates in combination with one-fourth the MIC of cefoxitina
Isolate No. of clonestested
MIC (g/ml)
OXA 48 h FOX 48 h OXA  1/4 MICFOX 24 h
OXA  1/4 MIC
FOX 48 h
OXA  1/4 MIC
CXM 48 h
MW2 (USA400) (CA-MRSA) 3 64 64 1 1 64
USA300 (CA-MRSA) 3 64 64 1 1 64
COL (HA-MRSA) 3 256 128 32 64 NA
MRSA252 (HA-MRSA) 3 256 128 64 128 NA
Mu50 (HA-MRSA/VISA) 3 256 256 128 256 NA
CA-MRSA strains 30 64b 64b 1 1 NA
CA-MRSA from CSSTI 30c 64b 64b 1 1 NA
HA-MRSA strains 30 256b 128b 32b 64b NA
a Cefoxitin exerts a synergistic effect with oxacillin on CA-MRSA strains, while cefuroxime, a -lactam with very low affinity for PBP4, did not yield a similar outcome.
MICs were determined with cultures grown overnight diluted in CSMHB with 0.25	 MIC of cefoxitin in 96 microtiter wells to achieve a final concentration of 5 	
105 CFU/ml. All serial dilutions were plated onto antibiotic-free agar to confirm the inocula. Growth was checked after 24 and 48 h. NA, not applicable.
b MIC data for all clinical isolates were reported as median values from at least three independent experiments.
c Two CSSTI isolates showed MICs for this combination higher than those of the rest of the tested strains (MIC oxacillin was 4 g/ml compared to 1 g/ml, still
several times below the maximum achievable concentration in vivo).
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and MW0047) identified 30 isolates that were positive for these
genes. All 30 isolates exhibited the synergistic inhibitory effect
of cefoxitin and oxacillin, with 27 strains (90%) being unable to
grow at 1 g/ml of oxacillin after 24 and/or 48 h, and the
remaining three grew at 1, 4, and 8 g/ml of oxacillin with
0.25	 MIC of cefoxitin after 48 h (Table 3). The HA-MRSA
isolates that tested negative for the above-mentioned genes
(but positive for mecA) grew in oxacillin concentrations rang-
ing from 4 to 128 g/ml (median values at 32 and 64 g/ml at
24 and 48 h, respectively) in the presence of cefoxitin. The code
was subsequently broken, confirming that all 30 isolates, des-
ignated by us as being CA-MRSA isolates, originated from
patients with primary skin infections and annotated by the
hospital as being CA-MRSA, while the other isolates were
blood isolates designated HA-MRSA isolates. We further
tested this synergistic inhibitory activity on 30 MRSA isolates
from CSSTI, with CA-MRSA being the most common etiolog-
ical agent. The MICs of cefoxitin for all strains were first
obtained, and one-fourth of the median value was used to test
the synergistic inhibitory activity with oxacillin. The MICs of
oxacillin for 28 of them were 1 g/ml when one-fourth the
MIC of cefoxitin was added. Two isolates presented slightly
higher values, with an MIC of 4 g/ml, which we found to be
attributable to a higher level of resistance to cefoxitin.
DISCUSSION
CA-MRSA isolates s were initially associated with lethal
infections in children in the Midwest (21). CA-MRSA strains
have since become the most frequent cause of skin and soft
tissue infections in emergency rooms in the United States,
increasing in frequency from 29% in 2001 to 2002 to 64% in
2003 to 2004 (32, 43, 44). However, the epidemiology of
MRSA disease is changing, with the pulsed-field type USA300
now being the most common strain in the community but also
emerging as a major cause of nosocomial bloodstream and
prosthetic joint infections (33, 52). These epidemiological data
underline the need to study the molecular mechanisms of vir-
ulence and drug resistance in this strain. PBP4, although not
essential for viability, has been associated with low-level resis-
tance to vancomycin and -lactam antibiotics in HA-MRSA
strain COL (11, 22, 24, 30, 45, 53). However, a mutation in
pbp4, but not pbp3, in MW2 and USA300 strains has led to a
significant decrease in high-level resistance to the penicilli-
nase-stable antibiotics oxacillin and nafcillin, but this alteration
in resistance was not observed in pbp3, pbp4, or double mu-
tants of HA-MRSA strain COL. More specifically, there was a
16-fold reduction in oxacillin and nafcillin MICs (from 64 to 4
g/ml and from 16 to 1 g/ml, respectively) in pbp4 mutants of
MW2 and USA300, while a pbp3 deletion had no effect. Re-
markably, a pbp4 mutation in HA-MRSA strain N315 and
VISA strain Mu50 also did not result in decreased MICs of
oxacillin.
The major contribution of PBP4 to resistance in CA-MRSA
strains was validated by our findings that mecA expression
remained unchanged in the pbp4 mutants. The overexpression
of mecA in inducible plasmid pEPSA5 did not complement
-lactam resistance in either the pbp4 or the pbp3 pbp4 mutant,
with their MICs of oxacillin being unchanged. The loss of
PBP4 in MW2 ex, an MW2 strain lacking plasmid pMW2 and
constitutively expressing mecA in a manner similar to that of
COL, was also found to have decreased oxacillin resistance
(pbp4 MIC of 2 g/ml versus 128 g/ml in MW2 ex), more so
FIG. 6. Population analysis of susceptibility to oxacillin (A), cefox-
itin (B), and oxacillin combined to one-fourth the MIC of cefoxitin
(C) for wild-type strain MW2. Antibiotic susceptibilities of strains were
determined in cultures grown overnight plated onto agar containing
different concentrations of oxacillin, cefoxitin, or one-fourth the MIC
of cefoxitin with twofold dilutions of oxacillin and incubated at 37°C
for 48 h.
TABLE 4. MBCs of oxacillin, cefoxitin, and oxacillin in combination
with one-fourth the MIC of cefoxitin for wild-type CA-MRSA
and HA-MRSA strainsa
Strain
No. of
clones
tested
MBCb g/ml
OXA
48 h
FOX
48 h
OXA  1/4
MIC FOX
48 h
MW2 (USA400) (CA-MRSA) 3 256 256 1
USA300 (CA-MRSA) 3 256 256 1
COL (HA-MRSA) 3 256 256 256
MRSA252 (HA-MRSA) 3 256 256 256
Mu50 (HA-MRSA/VISA) 3 256 256 256
a MBC was assessed by plating the broth from the MIC wells and from those
wells above the MIC for each strain onto appropriate drug-free growth media
after 48 h and incubated at 37°C for 24 h. OXA, oxacillin; FOX, cefoxitin.
b MIC data for all clinical isolates were reported as median values from at least
three independent experiments.
VOL. 52, 2008 PBP4 AND METHICILLIN RESISTANCE IN CA-MRSA STRAINS 3963
than the parental MW2 strain (pbp4 with MIC of 4 g/ml
versus 64 g/ml in MW2), where mecA is under the regulation
of the blaIRZ operon on plasmid pMW2. This observation
suggests that the constitutive expression of PBP2A did not
contribute to oxacillin resistance in community-acquired
strains in the absence of PBP4.
Although the loss of pbp4 in CA-MRSA strain MW2 affects
the transcription of pbp2 in cells challenged with oxacillin, this
was not the only factor contributing to the resistance mecha-
nism, since the complementation of pbp2 in trans did not re-
store -lactam resistance to the parental level in either the
pbp4 or the pbp3 pbp4 mutant. We have ruled out the possi-
bility that the difference in pbp2 transcription between COL
and MW2 might be due to polar effects upstream and/or down-
stream of the deleted pbp4 region. We also evaluated the only
PBP2 regulator described so far, i.e., the two-component reg-
ulatory system vraSR (36), which was found to be upregulated
in all strains in the presence of oxacillin. We are currently
investigating if genes present in either the type I SCCmec of
COL or type IV SCCmec could be the reason behind such a
striking difference not only in pbp2 expression but also in
oxacillin resistance between CA-MRSA and HA-MRSA iso-
lates in the absence of PBP4.
Our data here confirm the previously reported cooperative
activity of PBP2, PBP4, and PBP2A and add a link in tran-
scription between pbp4 and the innate pbp2 (37). Our results
also showed that the increase in sensitivity to -lactams asso-
ciated with the loss of pbp4 is not due to increased autolysis.
HPLC analysis of peptidoglycan muropeptides confirmed that
the loss of PBP4 in MW2 was associated with a reduction in
peptidoglycan cross-linking and, hence, an increase in the per-
centage of monomeric, dimeric, and trimeric muropeptides
compared to that of the parental strain (Fig. 5). We also
carried out muropeptide analysis of pbp4 mutants of HA-
MRSA strain COL and methicillin-sensitive S. aureus strain
Newman and found a lesser reduction in the percentage of
highly cross-linked muropeptides than with the pbp4 mutant of
MW2 (data not shown).
Given the role of PBP4 in mediating resistance to -lactams
in CA-MRSA strains, we assessed whether a strategy against
PBP4 could lead to a plausible therapeutic approach against
them. Cefoxitin, which binds PBP4 irreversibly, was found to
be synergistic with oxacillin at killing CA-MRSA strains com-
pared to oxacillin alone. In the presence of one-fourth the MIC
of cefoxitin, the MIC of oxacillin went down 64-fold, from 64
g/ml to 1 g/ml; an even more significant drop was found for
MBC with both USA300 and MW2, from 256 g/ml to 1
g/ml. The fact that both cefoxitin and oxacillin have been
widely used for years, at MIC and MBC concentrations that
are easily achievable in vivo for CA-MRSA, strongly reinforces
their therapeutic potential. The efficacy of this synergistic com-
bination on other CA-MRSA isolates was subsequently tested
on 200 MRSA isolates from Dartmouth-Hitchcock Medical
Center, Lebanon, NH, blinded with respect to the origin. All
the isolates that were found to be community acquired with our
genetic screen were sensitive to a combination of oxacillin and
cefoxitin. The code was subsequently broken, confirming that
all 30 isolates, designated by us as being CA-MRSA isolates,
were obtained from patients with primary skin infections and
annotated by the hospital as being CA-MRSA isolates. We
further confirmed this approach by testing this combination on
30 additional MRSA isolates that caused CSSTI (Table 3) and
that were positive for our genetic markers. These CSSTI iso-
lates were again sensitive to the combined action of cefoxitin
and oxacillin. There were only two isolates whose MICs for this
combination were higher than those for the rest of the tested
strains (MIC of oxacillin of 4 g/ml compared to 1 g/ml but
still significantly below the maximum achievable concentration
in vivo). The genetic reason for this small increase in these two
strains is not entirely clear but may be due to a higher level of
resistance to cefoxitin.
Collectively, our results clearly demonstrate that PBP4 is a
key element in -lactam resistance in CA-MRSA strains. We
also showed that PBP2A, the product of mecA, is not the sole
determinant for oxacillin resistance in these isolates. Accord-
ingly, cefoxitin may be used in combination with synthetic
penicillins to treat CA-MRSA infections. Additionally, this
antibiotic profile on sensitivity to a combination of cefoxitin
and oxacillin can also be used as a tool to screen clinical
specimens for CA-MRSA strains. An understanding of the
genetic determinants that account for the difference in resis-
tance between CA-MRSA and HA-MRSA strains will be vital
for the development of novel strategies against staphylococcal
infections.
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